ChloroquineV1, PubMed, Checkpoint, bibRecord, 000004

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Identifieur interne : 000004 ( PubMed/Checkpoint ); précédent : 000003; suivant : 000005

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Source :

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2020.

RBID : pubmed:32150618

Abstract

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.

DOI: 10.1093/cid/ciaa237
PubMed: 32150618

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000002
to stream PubMed, to step Curation: 000002

Links to Exploration step

pubmed:32150618

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).</title>
<author><name sortKey="Yao, Xueting" sort="Yao, Xueting" uniqKey="Yao X" first="Xueting" last="Yao">Xueting Yao</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ye, Fei" sort="Ye, Fei" uniqKey="Ye F" first="Fei" last="Ye">Fei Ye</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhang, Miao" sort="Zhang, Miao" uniqKey="Zhang M" first="Miao" last="Zhang">Miao Zhang</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cui, Cheng" sort="Cui, Cheng" uniqKey="Cui C" first="Cheng" last="Cui">Cheng Cui</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huang, Baoying" sort="Huang, Baoying" uniqKey="Huang B" first="Baoying" last="Huang">Baoying Huang</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niu, Peihua" sort="Niu, Peihua" uniqKey="Niu P" first="Peihua" last="Niu">Peihua Niu</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Liu, Xu" sort="Liu, Xu" uniqKey="Liu X" first="Xu" last="Liu">Xu Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhao, Li" sort="Zhao, Li" uniqKey="Zhao L" first="Li" last="Zhao">Li Zhao</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dong, Erdan" sort="Dong, Erdan" uniqKey="Dong E" first="Erdan" last="Dong">Erdan Dong</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Song, Chunli" sort="Song, Chunli" uniqKey="Song C" first="Chunli" last="Song">Chunli Song</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Orthopedics, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Orthopedics, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhan, Siyan" sort="Zhan, Siyan" uniqKey="Zhan S" first="Siyan" last="Zhan">Siyan Zhan</name>
<affiliation wicri:level="3"><nlm:affiliation>Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lu, Roujian" sort="Lu, Roujian" uniqKey="Lu R" first="Roujian" last="Lu">Roujian Lu</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Haiyan" sort="Li, Haiyan" uniqKey="Li H" first="Haiyan" last="Li">Haiyan Li</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Liu, Dongyang" sort="Liu, Dongyang" uniqKey="Liu D" first="Dongyang" last="Liu">Dongyang Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32150618</idno>
<idno type="pmid">32150618</idno>
<idno type="doi">10.1093/cid/ciaa237</idno>
<idno type="wicri:Area/PubMed/Corpus">000002</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000002</idno>
<idno type="wicri:Area/PubMed/Curation">000002</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000002</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000004</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000004</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).</title>
<author><name sortKey="Yao, Xueting" sort="Yao, Xueting" uniqKey="Yao X" first="Xueting" last="Yao">Xueting Yao</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ye, Fei" sort="Ye, Fei" uniqKey="Ye F" first="Fei" last="Ye">Fei Ye</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhang, Miao" sort="Zhang, Miao" uniqKey="Zhang M" first="Miao" last="Zhang">Miao Zhang</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cui, Cheng" sort="Cui, Cheng" uniqKey="Cui C" first="Cheng" last="Cui">Cheng Cui</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huang, Baoying" sort="Huang, Baoying" uniqKey="Huang B" first="Baoying" last="Huang">Baoying Huang</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niu, Peihua" sort="Niu, Peihua" uniqKey="Niu P" first="Peihua" last="Niu">Peihua Niu</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Liu, Xu" sort="Liu, Xu" uniqKey="Liu X" first="Xu" last="Liu">Xu Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhao, Li" sort="Zhao, Li" uniqKey="Zhao L" first="Li" last="Zhao">Li Zhao</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dong, Erdan" sort="Dong, Erdan" uniqKey="Dong E" first="Erdan" last="Dong">Erdan Dong</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Song, Chunli" sort="Song, Chunli" uniqKey="Song C" first="Chunli" last="Song">Chunli Song</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Orthopedics, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Orthopedics, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhan, Siyan" sort="Zhan, Siyan" uniqKey="Zhan S" first="Siyan" last="Zhan">Siyan Zhan</name>
<affiliation wicri:level="3"><nlm:affiliation>Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lu, Roujian" sort="Lu, Roujian" uniqKey="Lu R" first="Roujian" last="Lu">Roujian Lu</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Haiyan" sort="Li, Haiyan" uniqKey="Li H" first="Haiyan" last="Li">Haiyan Li</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<affiliation wicri:level="3"><nlm:affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Liu, Dongyang" sort="Liu, Dongyang" uniqKey="Liu D" first="Dongyang" last="Liu">Dongyang Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Drug Clinical Trial Center, Peking University Third Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title>
<idno type="eISSN">1537-6591</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32150618</PMID>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Mar</Month>
<Day>09</Day>
</PubDate>
</JournalIssue>
<Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
<ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">ciaa237</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciaa237</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than chloroquine (EC50=5.47 μM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.</AbstractText>
<CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName>
<ForeName>Xueting</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ye</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Miao</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cui</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Huang</LastName>
<ForeName>Baoying</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Niu</LastName>
<ForeName>Peihua</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Xu</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhao</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dong</LastName>
<ForeName>Erdan</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Song</LastName>
<ForeName>Chunli</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Orthopedics, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhan</LastName>
<ForeName>Siyan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Roujian</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Haiyan</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Wenjie</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Dongyang</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>03</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Infect Dis</MedlineTA>
<NlmUniqueID>9203213</NlmUniqueID>
<ISSNLinking>1058-4838</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chloroquine</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>02</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
<ArticleId IdType="pii">5801998</ArticleId>
<ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Yao, Xueting" sort="Yao, Xueting" uniqKey="Yao X" first="Xueting" last="Yao">Xueting Yao</name>
</noRegion>
<name sortKey="Cui, Cheng" sort="Cui, Cheng" uniqKey="Cui C" first="Cheng" last="Cui">Cheng Cui</name>
<name sortKey="Dong, Erdan" sort="Dong, Erdan" uniqKey="Dong E" first="Erdan" last="Dong">Erdan Dong</name>
<name sortKey="Huang, Baoying" sort="Huang, Baoying" uniqKey="Huang B" first="Baoying" last="Huang">Baoying Huang</name>
<name sortKey="Li, Haiyan" sort="Li, Haiyan" uniqKey="Li H" first="Haiyan" last="Li">Haiyan Li</name>
<name sortKey="Liu, Dongyang" sort="Liu, Dongyang" uniqKey="Liu D" first="Dongyang" last="Liu">Dongyang Liu</name>
<name sortKey="Liu, Xu" sort="Liu, Xu" uniqKey="Liu X" first="Xu" last="Liu">Xu Liu</name>
<name sortKey="Lu, Roujian" sort="Lu, Roujian" uniqKey="Lu R" first="Roujian" last="Lu">Roujian Lu</name>
<name sortKey="Niu, Peihua" sort="Niu, Peihua" uniqKey="Niu P" first="Peihua" last="Niu">Peihua Niu</name>
<name sortKey="Song, Chunli" sort="Song, Chunli" uniqKey="Song C" first="Chunli" last="Song">Chunli Song</name>
<name sortKey="Tan, Wenjie" sort="Tan, Wenjie" uniqKey="Tan W" first="Wenjie" last="Tan">Wenjie Tan</name>
<name sortKey="Ye, Fei" sort="Ye, Fei" uniqKey="Ye F" first="Fei" last="Ye">Fei Ye</name>
<name sortKey="Zhan, Siyan" sort="Zhan, Siyan" uniqKey="Zhan S" first="Siyan" last="Zhan">Siyan Zhan</name>
<name sortKey="Zhang, Miao" sort="Zhang, Miao" uniqKey="Zhang M" first="Miao" last="Zhang">Miao Zhang</name>
<name sortKey="Zhao, Li" sort="Zhao, Li" uniqKey="Zhao L" first="Li" last="Zhao">Li Zhao</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000004 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000004 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:32150618
   |texte=   In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:32150618" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki